产品封面图

pIB/V5-His-TOPO

收藏
  • ¥800 - 1200
  • Ybscience
  • 中国/美国
  • YB-0760
  • 2025年07月15日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      -20℃

    • 保质期

      6个月

    • 英文名

      pIB/V5-His-TOPO

    • 库存

      大量

    • 供应商

      钰博生物

    • 规格

      1ug/5ug

    pIB/V5-His-TOPO

    载体基本信息

    出品公司: Ybscience
    载体名称: pIB/V5-His-TOPO
    质粒类型: 昆虫表达载体;TOPO-TA克隆载体
    克隆方法: TOPO-TA
    启动子: OplE2
    载体大小: 3537bp
    5' 测序引物及序列: OplE2 Forward:5'd[CGCAACGATCTGGTAAACAC]3'
    3' 测序引物及序列: --
    载体标签: V5 Epitope Tag, His Tag (C-末端)
    载体抗性: 氨苄青霉素
    真核筛选标记: Blasticidin
    克隆菌株: TOP10
    宿主细胞(系): Sf9,Sf21,HighFive
    备注: --
    瞬表达/稳表达: 稳表达
    组成型/诱导型: 组成型
    病毒/非病毒: 非病毒
     

    载体质粒图谱和多克隆位点信息

    pIB-V5-His-TOPO 载体图谱



    pIB-V5-His-TOPO 多克隆位点

    pIB-V5-His-TOPO 载体特征

    载体简介

     

    描述
    The pIB/V5-His TOPO® TA Expression Kit offers five-minute cloning of Taq-amplified PCR products directly into the pIB/V5-His-TOPO expression vector. In addition to being TOPO Cloning ready, pIB/V5-His-TOPO includes:
    
    • The OpIE2 promoter for constitutive expression
    • The Blasticidin resistance gene for rapid selection of stably transfected cell lines in two weeks
    • C-terminal V5 epitope and polyhistidine (6xHis) sequence for detection with Invitrogen's Anti-V5 Antibody and rapid purification using nickel-chelating resin
    
    表达水平
    The OpIE2 promoter provides relatively high levels of constitutive expression, although not all proteins will express as high as might be expected from baculovirus late promoters such as polyhedrin or very late promoters such as p10 (Jarvis et al., 1996).
    However, some researchers have found that the InsectSelect™ System expresses some proteins better than baculovirus systems. To date, reported expression levels range from 1-2 µg/ml (human IL-6; Invitrogen) to 8-10 µg/ml (human melanotransferrin) (Hegeduset al., 1999). 
    

     

    载体序列

    LOCUS       pIB/V5-His-TOPO	3537 bp 	DNA	SYN
    DEFINITION  pIB/V5-His-TOPO
    ACCESSION   
    KEYWORDS    
    SOURCE      
      ORGANISM  other sequences; artificial sequences; vectors.
    FEATURES             Location/Qualifiers
         source          1..3537
                         /organism="pIB/V5-His-TOPO"
                         /mol_type="other DNA"
         misc_feature    511..530
                         /label="OpIE2_fwd_primer"
         rep_origin      complement(1003..1622)
                         /label="pBR322_origin"
         promoter        1996..2063
                         /label="EM7_promoter"
         gene            2064..2462
                         /label="blast (variant)"
                         /gene="blast (variant)"
         gene            2582..3442
                         /label="Ampicillin"
                         /gene="Ampicillin"
         CDS             2582..3442
                         /label="ORF frame 2"
                         /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                         IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                         YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                         DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                         LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                         EIGASLIKHW*"
    ORIGIN
        1 CATGATGATA AACAATGTAT GGTGCTAATG TTGCTTCAAC AACAATTCTG TTGAACTGTG
       61 TTTTCATGTT TGCCAACAAG CACCTTTATA CTCGGTGGCC TCCCCACCAC CAACTTTTTT
      121 GCACTGCAAA AAAACACGCT TTTGCACGCG GGCCCATACA TAGTACAAAC TCTACGTTTC
      181 GTAGACTATT TTACATAAAT AGTCTACACC GTTGTATACG CTCCAAATAC ACTACCACAC
      241 ATTGAACCTT TTTGCAGTGC AAAAAAGTAC GTGTCGGCAG TCACGTAGGC CGGCCTTATC
      301 GGGTCGCGTC CTGTCACGTA CGAATCACAT TATCGGACCG GACGAGTGTT GTCTTATCGT
      361 GACAGGACGC CAGCTTCCTG TGTTGCTAAC CGCAGCCGGA CGCAACTCCT TATCGGAACA
      421 GGACGCGCCT CCATATCAGC CGCGCGTTAT CTCATGCGCG TGACCGGACA CGAGGCGCCC
      481 GTCCCGCTTA TCGCGCCTAT AAATACAGCC CGCAACGATC TGGTAAACAC AGTTGAACAG
      541 CATCTGTTCG AATTTAAAGC TTGGTACCGA GCTCGGATCC ACTAGTCCAG TGTGGTGGAA
      601 TTGCCCTTAA GGGCAATTCT GCAGATATCC AGCACAGTGG CGGCCGCTCG AGTCTAGAGG
      661 GCCCGCGGTT CGAAGGTAAG CCTATCCCTA ACCCTCTCCT CGGTCTCGAT TCTACGCGTA
      721 CCGGTCATCA TCACCATCAC CATTGAGTTT ATCTGACTAA ATCTTAGTTT GTATTGTCAT
      781 GTTTTAATAC AATATGTTAT GTTTAAATAT GTTTTTAATA AATTTTATAA AATAATTTCA
      841 ACTTTTATTG TAACAACATT GTCCATTTAC ACACTCCTTT CAAGCGCGTG GGATCGATGC
      901 TCACTCAAAG GCGGTAATAC GGTTATCCAC AGAATCAGGG GATAACGCAG GAAAGAACAT
      961 GTGAGCAAAA GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT
     1021 CCATAGGCTC CGCCCCCCTG ACGAGCATCA CAAAAATCGA CGCTCAAGTC AGAGGTGGCG
     1081 AAACCCGACA GGACTATAAA GATACCAGGC GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC
     1141 TCCTGTTCCG ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT
     1201 GGCGCTTTCT CATAGCTCAC GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA
     1261 GCTGGGCTGT GTGCACGAAC CCCCCGTTCA GCCCGACCGC TGCGCCTTAT CCGGTAACTA
     1321 TCGTCTTGAG TCCAACCCGG TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA
     1381 CAGGATTAGC AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA
     1441 CTACGGCTAC ACTAGAAGAA CAGTATTTGG TATCTGCGCT CTGCTGAAGC CAGTTACCTT
     1501 CGGAAAAAGA GTTGGTAGCT CTTGATCCGG CAAACAAACC ACCGCTGGTA GCGGTGGTTT
     1561 TTTTGTTTGC AAGCAGCAGA TTACGCGCAG AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT
     1621 CTTTTCTACG GGGTCTGACG CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT
     1681 GCGAAACACG CACGGCGCGC GCACGCAGCT TAGCACAAAC GCGTCGTTGC ACGCGCCCAC
     1741 CGCTAACCGC AGGCCAATCG GTCGGCCGGC CTCATATCCG CTCACCAGCC GCGTCCTATC
     1801 GGGCGCGGCT TCCGCGCCCA TTTTGAATAA ATAAACGATA ACGCCGTTGG TGGCGTGAGG
     1861 CATGTAAAAG GTTACATCAT TATCTTGTTC GCCATCCGGT TGGTATAAAT AGACGTTCAT
     1921 GTTGGTTTTT GTTTCAGTTG CAAGTTGGCT GCGGCGCGCG CAGCACCTTT GCCGGGATCT
     1981 GCCGGGCTGC AGCACGTGTT GACAATTAAT CATCGGCATA GTATATCGGC ATAGTATAAT
     2041 ACGACAAGGT GAGGAACTAA ACCATGGCCA AGCCTTTGTC TCAAGAAGAA TCCACCCTCA
     2101 TTGAAAGAGC AACGGCTACA ATCAACAGCA TCCCCATCTC TGAAGACTAC AGCGTCGCCA
     2161 GCGCAGCTCT CTCTAGCGAC GGCCGCATCT TCACTGGTGT CAATGTATAT CATTTTACTG
     2221 GGGGACCTTG CGCAGAACTC GTGGTGCTGG GCACTGCTGC TGCTGCGGCA GCTGGCAACC
     2281 TGACTTGTAT CGTCGCGATC GGAAATGAGA ACAGGGGCAT CTTGAGCCCC TGCGGACGGT
     2341 GCCGACAGGT TCTTCTCGAT CTGCATCCTG GGATCAAAGC CATAGTGAAG GACAGTGATG
     2401 GACAGCCGAC GGCAGTTGGG ATTCGTGAAT TGCTGCCCTC TGGTTATGTG TGGGAGGGCT
     2461 AAGCACTTCG TGGCCGAGGA GCAGGACTGA CACGTCCCGG GAGATCTGCA TGTCTACTAA
     2521 ACTCACAAAT TAGAGCTTCA ATTTAATTAT ATCAGTTATT ACCCATTGAA AAAGGAAGAG
     2581 TATGAGTATT CAACATTTCC GTGTCGCCCT TATTCCCTTT TTTGCGGCAT TTTGCCTTCC
     2641 TGTTTTTGCT CACCCAGAAA CGCTGGTGAA AGTAAAAGAT GCTGAAGATC AGTTGGGTGC
     2701 ACGAGTGGGT TACATCGAAC TGGATCTCAA CAGCGGTAAG ATCCTTGAGA GTTTTCGCCC
     2761 CGAAGAACGT TTTCCAATGA TGAGCACTTT TAAAGTTCTG CTATGTGGCG CGGTATTATC
     2821 CCGTATTGAC GCCGGGCAAG AGCAACTCGG TCGCCGCATA CACTATTCTC AGAATGACTT
     2881 GGTTGAGTAC TCACCAGTCA CAGAAAAGCA TCTTACGGAT GGCATGACAG TAAGAGAATT
     2941 ATGCAGTGCT GCCATAACCA TGAGTGATAA CACTGCGGCC AACTTACTTC TGACAACGAT
     3001 CGGAGGACCG AAGGAGCTAA CCGCTTTTTT GCACAACATG GGGGATCATG TAACTCGCCT
     3061 TGATCGTTGG GAACCGGAGC TGAATGAAGC CATACCAAAC GACGAGCGTG ACACCACGAT
     3121 GCCTGTAGCA ATGGCAACAA CGTTGCGCAA ACTATTAACT GGCGAACTAC TTACTCTAGC
     3181 TTCCCGGCAA CAATTAATAG ACTGGATGGA GGCGGATAAA GTTGCAGGAC CACTTCTGCG
     3241 CTCGGCCCTT CCGGCTGGCT GGTTTATTGC TGATAAATCT GGAGCCGGTG AGCGTGGGTC
     3301 TCGCGGTATC ATTGCAGCAC TGGGGCCAGA TGGTAAGCCC TCCCGTATCG TAGTTATCTA
     3361 CACGACGGGG AGTCAGGCAA CTATGGATGA ACGAAATAGA CAGATCGCTG AGATAGGTGC
     3421 CTCACTGATT AAGCATTGGT AACTGTCAGA CCAAGTTTAC TCATATATAC TTTAGATTGA
     3481 TTTAAAACTT CATTTTTAAT TTAAAAGGAT CTAGGTGAAG ATCCTTTTTG ATAATCT

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • 【求助】关于gsk3-beta功能的疑问

      a look from the following website just by clicking "Tyrosine Phosphorylation and Dimerization" http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WSN-43F85YV-2&_user=1111158&_coverDate=06%2F29%2F2001&_rdoc=1&_fmt=full&_orig=search

    • 胞内晶体蛋白基因的酿酒酵母真核表达

        1. 重组供载体pCR4-TOPO-cipA及pCR4-TOPO-cipB; 2. 酵母表达载体pYES2.1/V5-His-TOPO,美国Invitrogen公司; 3. 大肠杆菌Escherichia. coli TOP10F’,美国Invitrogen公司; 4. 酿酒酵母Saccharomyces cerevisiae INVSc1。 实验步骤   1. 重组穿梭载体的构建 按照质粒提取方法提取

    • 【精华】vol 687 Chapter 3 采用Splinkerette-PCR技术对前病毒基因组插入位点进行分离

      of PCR are performed followed by PCR products cloning and sequencing. (b) SplinkBlunt-PCR protocol. Genomic DNA (horizontal lines) is digested with restriction enzymes (X, Y, and Z in this case)in a similar way described in (a). After the digested double

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥800
    上海钰博生物科技有限公司
    2025年07月15日询价
    ¥1
    上海联迈生物工程有限公司
    2025年07月13日询价
    ¥1980
    上海晶风生物科技有限公司
    2025年07月11日询价
    ¥800
    南京诺唯赞生物科技股份有限公司
    2025年12月28日询价
    询价
    NEB(北京)
    2025年12月28日询价
    pIB/V5-His-TOPO
    ¥800 - 1200